{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:00:13Z","timestamp":1784138413058,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018944","name":"Grupo Ferrer Internacional, S.A","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.lanepe.2025.101348","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:52:57Z","timestamp":1751021577000},"page":"101348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial"],"prefix":"10.1016","volume":"55","author":[{"given":"Thomas","family":"Gaziano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-6537","authenticated-orcid":false,"given":"Amy","family":"Dymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Looby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0000-7109","authenticated-orcid":false,"given":"Alberto","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fern\u00e1ndez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Schiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Doehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Ojeda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2025.101348_bib1","series-title":"StatPearls","article-title":"Acute myocardial infarction. 2023 Sep 3","author":"Mechanic","year":"2025"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101348_bib2","first-page":"414","article-title":"Long-term mortality and hospital readmission after acute myocardial infarction: an eight-year follow-up study","volume":"65","author":"Andres","year":"2012","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.lanepe.2025.101348_bib3","unstructured":"Ministerio de Sanidad. Informe Anual del Sistema Nacional de Salud 2020-2021;2023."},{"issue":"38","key":"10.1016\/j.lanepe.2025.101348_bib4","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101348_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurjpc\/zwac204","article-title":"How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European association of preventive cardiology","volume":"30","author":"Pedretti","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"20","key":"10.1016\/j.lanepe.2025.101348_bib6","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A Polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"10306","key":"10.1016\/j.lanepe.2025.101348_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101348_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2025.101348_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2022.05.015","article-title":"The CV-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study","volume":"361","author":"Gonz\u00e1lez-Juanatey","year":"2022","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.lanepe.2025.101348_bib10","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.lanepe.2025.101348_bib11","year":"2023"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101348_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101348_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","article-title":"Spanish recommendations on economic evaluation of health technologies","volume":"11","author":"L\u00f3pez-Bastida","year":"2010","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101348_bib14","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.lanepe.2025.101348_bib15","series-title":"Evidence review for dual antiplatelet therapy: acute coronary syndromes: evidence review A","year":"2020"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101348_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/jech.57.8.622","article-title":"Continuing inequality: gender and social class influences on self perceived health after a heart attack","volume":"57","author":"Lacey","year":"2003","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101348_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)","volume":"7","author":"Samuel","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"12","key":"10.1016\/j.lanepe.2025.101348_bib23","first-page":"1027","article-title":"Cost-effectiveness and budget impact of treatment with evolocumab versus statins and ezetimibe for hypercholesterolemia in Spain","volume":"71","author":"de Labry Lima","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101348_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40273-017-0607-0","article-title":"Ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction: an evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Pouwels","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101348_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.lanepe.2025.101348_bib30","author":"Szende"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101348_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.36469\/jheor.2022.39768","article-title":"Cost-effectiveness of the CV-polypill strategy compared with separate monocomponents in secondary prevention of cardiovascular and cerebrovascular disease in Portugal: the MERCURY study","volume":"9","author":"Aguiar","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101348_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.recesp.2016.05.011","article-title":"Usefulness of a cardiovascular polypill in the treatment of secondary prevention patients in Spain: a cost-effectiveness study","volume":"70","author":"Barrios","year":"2017","journal-title":"Rev Esp Cardiol"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101348_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007111","article-title":"Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK","volume":"5","author":"Becerra","year":"2015","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101348_bib35","first-page":"414","article-title":"Cost-effectiveness of the CV-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain","volume":"223","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2023","journal-title":"Rev Cl\u00edn Esp (Barc)"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101348_bib36","first-page":"306","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","year":"2024","journal-title":"Lancet"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225001401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225001401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:10:34Z","timestamp":1773353434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776225001401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":26,"alternative-id":["S2666776225001401"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101348","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101348"}}